Gotham__Org Gotham White.png
FHSI

Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index - 8 Item Version

For patients with Hepatobiliary cancer (liver, bile duct and pancreas); A FACT-Hepatobiliary Symptom Index (a subset of FACT-Hep containing 8 items)

 

Overview

Below are the details for the FHSI measure:

MEASURE NAME:

Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index - 8 Item Version (FHSI)

VERSION:

4

NUMBER OF ITEMS:

8

PATIENT POPULATION:

Hepatobiliary cancer patients 18 years and older

RECALL PERIOD:

Past 7 days

RESPONSE SCALE:

5 point Likert-type scale

DATA COLLECTION:

Paper and electronic

ADMINISTRATION:

Self-administration and interview when applicable

SUBSCALE DOMAINS:

Hepatobiliary cancer symptom index

TIME FOR COMPLETION:

Less than 5 minutes

SCORING:

Manual scoring template, some items are reverse scored. Total scores possible. SAS/SPSS algorithms available.

RELATED MEASURES:

Language Availability

Available translations of the FHSI can be obtained by registering for permission. Users are not permitted to translate the FHSI without permission from FACIT.org. Permission from FACIT.org to translate the FHSI may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system.

Please contact us for more information.

 
 

Licensing

Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained.

Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use.

To license an available version of this measure for commercial or non-commercial use, please complete our registration form. All of the information provided in the form will be kept strictly confidential. For questions, please contact us.

 

Selected References

Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J.  What are the most important symptom targets when treating advanced cancer?  A survey of providers in the National Comprehensive Cancer Network (NCCN).  Cancer Investigation 2003; 21(4): 526-535.  doi: 10.108/CNV-120022366.  


Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J.  Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer.  Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. 


Eid, S., Stromberg, A., Ames, S., Ellis, S., McMasters, K., & Martin, R.  Assessment of symptom experience in patients undergoing hepatic resection or ablation.  Cancer 2006; 107(11): 2715-2722. doi:  10.1002/cncr.22297.


Poplin, E., Feng, Y., Berlin, J., Rothenberg, M., Hochster, H., Mitchell, E., Alberts, S., O’Dwyer, P., Haller, D., Catalano, P., Cella, D., & Benson, A.  Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group.  Journal of Clinical Oncolology 2009; 27:3778-3785.  doi: 10.1200/JCO.2008.20.900.


Yount, S., Cella, D., Webster, K., Heffernan, N., Chang, C.-H., Odom, L., & van Gool, R.  Assessment of patient-reported clinical outcome in Pancreatic and other Hepatobiliary Cancers: The FACT Hepatobiliary Symptom Index.  Journal of Pain & Symptom Management 2002; 24(1): 32-44.  doi:  10.1016/s0885-3924(02)00422-0.  


Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R.  Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system.  Quality of Life Research 1996; 5: 309-320.


Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232.


Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85.


Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191.

 

Related Measures

FACT-Hep

Functional Assessment of Cancer Therapy – Hepatobiliary

NFHSI-18

National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index - 18 Item Version

FACT-G

Functional Assessment of Cancer Therapy – General

Gotham__Group-Gotham-White_SFW.png
Lauren Lent, DHA, MS
President, FACITtrans, LLC
Executive Director, FACIT.org
About Us
© 2020 FACIT.org 
Benjamin Arnold, MA
Executive Director, FACITtrans, LLC
Jason Bredle, MFA
Director, FACIT.org